Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

Inclusion Criteria: * Inpatient greater than or equal to (\>=) 18 years of age * Pathologically proven squamous cell carcinoma arising in the oropharynx, hypopharynx or larynx * Stage III or IV disease with an expected survival of at least 12 months * Medically suitable to withstand a course of concomitant boost RT * Presence of at least 1 bi-dimensionally measurable lesion identified either by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified World Health Organization (WHO) criteria * Karnofsky Performance Status (KPS) \>=80 at trial entry * Neutrophils \>=1.5\*10\^9/Liter (L), platelet count \>= 100\*10\^9/L, hemoglobin \>= 90 gram/liter (g/L) * Total bilirubin less than or equal to (\<=) 2\*upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<= 3\*ULN * Serum creatinine \<=133 micromole/liter (mcmol/L) * Serum calcium within normal range * Effective contraception if procreative potential exists (applicable to both male and female subjects) * Chinese with Chinese citizenship * Signed written informed consent Exclusion Criteria: * Evidence of distant metastatic disease * Squamous cell carcinoma arising in the nasopharynx or oral cavity * Receipt of prior systemic chemotherapy within the last 3 years * Previous surgery for the tumor under study other than biopsy * Receipt of prior RT to the head and neck * Currently receiving RT as part of a postoperative regimen following primary surgical resection * Planned neck dissection after trial RT * Active infection (infection requiring IV antibiotics), including active tuberculosis, or known and declared human immunodeficiency virus (HIV) * Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, cardiac failure or liver failure * Uncontrolled hypertension defined as systolic blood pressure \>=180 millimeter of mercury (mmHg) and/or diastolic blood pressure \>=130 mmHg under resting conditions * Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin \[beta-HCG\] test) or breastfeeding * Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy * Other concomitant anticancer therapies * Documented or symptomatic brain or leptomeningeal metastasis * Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency * Previous treatment with monoclonal antibody therapy, other signal transduction inhibitors or epidermal growth factor receptor (EGFR) targeting therapy * Evidence of previous other malignancy within the last 5 years * Intake of any investigational medication within 30 days before trial entry * Other protocol-defined exclusion criteria may apply